Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Sitryx licenses intellectual property rights for inhibitors of a new target in immunometabolism from Cancer Research UK in exclusive worldwide agreement Oxford, UK – 6 July 2021 – Sitryx (“the...
-
Sitryx further strengthens leadership team with the appointment of Iain Kilty, Ph.D., as Chief Scientific Officer Oxford, UK – 15 April 2021 – Sitryx (“the Company”), a biopharmaceutical company...
-
Sitryx appoints Pierre Legault as Chairman of its Board of Directors Oxford, UK – 24 March 2021 - Sitryx, a biopharmaceutical company focused on regulating cell metabolism to develop...
-
New biopharmaceutical company Sitryx launches with $30 million fundraising to develop disease modifying therapeutics in immunometabolism Fast-emerging area of research with potential to treat severe...
-
New biopharmaceutical company Sitryx launches with $30 million fundraising to develop disease modifying therapeutics in immunometabolism Fast-emerging area of research with potential to treat severe...